Mechanisms of metastasis

Breast Cancer Research

Volumn 10, Issue SUPPL. 1, 2008, Pages

  Hunter, Kent W ^a   Crawford, Nigel P S ^a   Alsarraj, Jude ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; DISEASE COURSE; HUMAN; METASTASIS; NEOPLASM; PATHOLOGY; REVIEW; TUMOR SUPPRESSOR GENE;

ANIMALS; DISEASE PROGRESSION; GENES, TUMOR SUPPRESSOR; HUMANS; NEOPLASM METASTASIS; NEOPLASMS;

EID: 58249092965     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr1988     Document Type: Review

References (91)

1. Al-Mehdi AB, Tozawa K, Fisher AB, Shientag L, Lee A, Muschel RJ. Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis. Nat Med 2000, 6:100-102.
2. Liotta LA, Stetler-Stevenson WG. Principles of Molecular Cell Biology of Cancer: Cancer Metastasis 1993, Philadelphia, PA: JB Lippincott Co., 4.
3. Schmidt-Kittler O, Ragg T, Daskalakis A, Granzow M, Ahr A, Blankenstein TJ, Kaufmann M, Diebold J, Arnholdt H, Muller P, Bischoff J, Harich D, Schlimok G, Riethmuller G, Eils R, Klein CA. From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci USA 2003, 100:7737-7742. 164657, 12808139.
4. Heimann R, Lan F, McBride R, Hellman S. Separating favorable from unfavorable prognostic markers in breast cancer: the role of E-cadherin. Cancer Res 2000, 60:298-304.
5. Heimann R, Hellman S. Clinical progression of breast cancer malignant behavior: what to expect and when to expect it. J Clin Oncol 2000, 18:591-599.
6. Butler TP, Gullino PM. Quantitation of cell shedding into efferent blood of mammary adenocarcinoma. Cancer Res 1975, 35:512-516.
7. Tarin D, Price JE, Kettlewell MG, Souter RG, Vass AC, Crossley B. Mechanisms of human tumor metastasis studied in patients with peritoneovenous shunts. Cancer Res 1984, 44:3584-3592.
8. Weiss L, Nannmark U, Johansson BR, Bagge U. Lethal deformation of cancer cells in the microcirculation: a potential rate regulator of hematogenous metastasis. Int J Cancer 1992, 50:103-107.
9. Luzzi KJ, MacDonald IC, Schmidt EE, Kerkvliet N, Morris VL, Chambers AF, Groom AC. Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol 1998, 153:865-873. 1853000, 9736035.
10. Riethmuller G, Klein CA. Early cancer cell dissemination and late metastatic relapse: clinical reflections and biological approaches to the dormancy problem in patients. Semin Cancer Biol 2001, 11:307-311.
11. Wong CW, Lee A, Shientag L, Yu J, Dong Y, Kao G, Al-Mehdi AB, Bernhard EJ, Muschel RJ. Apoptosis: an early event in metastatic inefficiency. Cancer Res 2001, 61:333-338.
12. Nowell PC. The clonal evolution of tumor cell populations. Science 1976, 194:23-28.
13. Fidler IJ, Kripke ML. Metastasis results from preexisting variant cells within a malignant tumor. Science 1977, 197:893-895.
14. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordon-Cardo C, Guise TA, Massague J. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003, 3:537-549.
15. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, Viale A, Olshen AB, Gerald WL, Massague J. Genes that mediate breast cancer metastasis to lung. Nature 2005, 436:518-524. 1283098, 16049480.
16. Minn AJ, Kang Y, Serganova I, Gupta GP, Giri DD, Doubrovin M, Ponomarev V, Gerald WL, Blasberg R, Massague J. Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest 2005, 115:44-55. 539194, 15630443.
17. Kauffman EC, Robinson VL, Stadler WM, Sokoloff MH, Rinker-Schaeffer CW. Metastasis suppression: the evolving role of metastasis suppressor genes for regulating cancer cell growth at the secondary site. J Urol 2003, 169:1122-1133.
18. Steeg PS. Metastasis suppressors alter the signal transduction of cancer cells. Nat Rev Cancer 2003, 3:55-63.
19. Wick W, Petersen I, Schmutzler RK, Wolfarth B, Lenartz D, Bierhoff E, Hümmerich J, Müller DJ, Stangl AP, Schramm J, Wiestler OD, von Deimling A. Evidence for a novel tumor suppressor gene on chromosome 15 associated with progression to a metastatic stage in breast cancer. Oncogene 1996, 12:973-978.
20. Sekita N, Suzuki H, Ichikawa T, Kito H, Akakura K, Igarashi T, Nakayama T, Watanabe M, Shiraishi T, Toyota M, Yoshie O, Ito H. Epigenetic regulation of the KAI1 metastasis suppressor gene in human prostate cancer cell lines. Jpn J Cancer Res 2001, 92:947-951.
21. Chambers AF, Harris JF, Ling V, Hill RP. Rapid phenotype variation in cells derived from lung metastases of KHT fibrosarcoma. Invasion Metastasis 1984, 4:225-237.
22. Harris JF, Chambers AF, Hill RP, Ling V. Metastatic variants are generated spontaneously at a high rate in mouse KHT tumor. Proc Natl Acad Sci USA 1982, 79:5547-5551. 346941, 6957880.
23. Weiss L. Metastatic inefficiency. Adv Cancer Res 1990, 54:159-211.
24. Trainer DL, Kline T, Hensler G, Greig R, Poste G. Clonal analysis of the malignant properties of B16 melanoma cells treated with the DNA hypomethylating agent 5-azacytidine. Clin Exp Metastasis 1988, 6:185-200.
25. Ishikawa M, Okada F, Hamada J, Hosokawa M, Kobayashi H. Changes in the tumorigenic and metastatic properties of tumor cells treated with quercetin or 5-azacytidine. Int J Cancer 1987, 39:338-342.
26. Kerbel RS, Frost P, Liteplo R, Carlow DA, Elliott BE. Possible epigenetic mechanisms of tumor progression: induction of high-frequency heritable but phenotypically unstable changes in the tumorigenic and metastatic properties of tumor cell populations by 5-azacytidine treatment. J Cell Physiol Suppl 1984, 3:87-97.
27. Olsson L, Forchhammer J. Induction of the metastatic phenotype in a mouse tumor model by 5-azacytidine, and characterization of an antigen associated with metastatic activity. Proc Natl Acad Sci USA 1984, 81:3389-3393. 345513, 6203119.
28. Stopper H, Pechan R, Schiffmann D. 5-azacytidine induces micronuclei in and morphological transformation of Syrian hamster embryo fibroblasts in the absence of unscheduled DNA synthesis. Mutat Res 1992, 283:21-28.
29. Frost P, Kerbel RS, Hunt B, Man S, Pathak S. Selection of metastatic variants with identifiable karyotypic changes from a nonmetastatic murine tumor after treatment with 2'-deoxy-5-azacytidine or hydroxyurea: implications for the mechanisms of tumor progression. Cancer Res 1987, 47:2690-2695.
30. Ried T, Heselmeyer-Haddad K, Blegen H, Schrock E, Auer G. Genomic changes defining the genesis, progression, and malignancy potential in solid human tumors: a phenotype/genotype correlation. Genes Chromosomes Cancer 1999, 25:195-204.
31. Fidler IJ. Critical determinants of cancer metastasis: rationale for therapy. Cancer Chemother Pharmacol 1999, 43(Suppl):S3-10.
32. Nakayama T, Taback B, Turner R, Morton DL, Hoon DS. Molecular clonality of in-transit melanoma metastasis. Am J Pathol 2001, 158:1371-1378.
33. Chambers AF, Wilson S. Use of NeoR B16F1 murine melanoma cells to assess clonality of experimental metastases in the immune-deficient chick embryo. Clin Exp Metastasis 1988, 6:171-182.
34. Cheung ST, Chen X, Guan XY, Wong SY, Tai LS, Ng IO, So S, Fan ST. Identify metastasis-associated genes in hepatocellular carcinoma through clonality delineation for multinodular tumor. Cancer Res 2002, 62:4711-4721.
35. Fidler IJ, Yano S, Zhang RD, Fujimaki T, Bucana CD. The seed and soil hypothesis: vascularisation and brain metastases. Lancet Oncol 2002, 3:53-57.
36. Talmadge JE, Wolman SR, Fidler IJ. Evidence for the clonal origin of spontaneous metastases. Science 1982, 217:361-363.
37. Fidler IJ, Talmadge JE. Evidence that intravenously derived murine pulmonary melanoma metastases can originate from the expansion of a single tumor cell. Cancer Res 1986, 46:5167-5171.
38. Nicolson GL, Dulski KM, Trosko JE. Loss of intercellular junctional communication correlates with metastatic potential in mammary adenocarcinoma cells. Proc Natl Acad Sci USA 1988, 85:473-476. 279572, 3422438.
39. Ito A, Katoh F, Kataoka TR, Okada M, Tsubota N, Asada H, Yoshikawa K, Maeda S, Kitamura Y, Yamasaki H, Nojima H. A role for heterologous gap junctions between melanoma and endothelial cells in metastasis. J Clin Invest 2000, 105:1189-1197. 315440, 10791993.
40. Mori M, Sawada N, Kokai Y, Satoh M. Role of tight junctions in the occurrence of cancer invasion and metastasis. Med Electron Microsc 1999, 32:193-198.
41. Wang W, Wyckoff JB, Frohlich VC, Oleynikov Y, Hüttelmaier S, Zavadil J, Cermak L, Bottinger EP, Singer RH, White JG, Segall JE, Condeelis JS. Single cell behavior in metastatic primary mammary tumors correlated with gene expression patterns revealed by molecular profiling. Cancer Res 2002, 62:6278-6288.
42. Wolf K, Mazo I, Leung H, Engelke K, von Andrian UH, Deryugina EI, Strongin AY, Brocker EB, Friedl P. Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis. J Cell Biol 2003, 160:267-277. 2172637, 12527751.
43. Pawelek JM. Tumour-cell fusion as a source of myeloid traits in cancer. Lancet Oncol 2005, 6:988-993.
44. Garcia-Olmo D, Garcia-Olmo DC. Functionality of circulating DNA: the hypothesis of genometastasis. Ann N Y Acad Sci 2001, 945:265-275.
45. Pawelek JM. Tumour cell hybridization and metastasis revisited. Melanoma Res 2000, 10:507-514.
46. Okazaki K, Holtzer H. Myogenesis: fusion, myosin synthesis, and the mitotic cycle. Proc Natl Acad Sci USA 1966, 56:1484-1490. 220007, 5339623.
47. Anderson JM. Multinucleated giant cells. Curr Opin Hematol 2000, 7:40-47.
48. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004, 4:71-78.
49. Munzarova M, Kovarik J. Is cancer a macrophage-mediated autoaggressive disease?. Lancet 1987, 1:952-954.
50. Pawelek J, Chakraborty A, Lazova R, Yilmaz Y, Cooper D, Brash D, Handerson T. Co-opting macrophage traits in cancer progression: a consequence of tumor cell fusion?. Contrib Microbiol 2006, 13:138-155.
51. Rachkovsky M, Sodi S, Chakraborty A, Avissar Y, Bolognia J, McNiff JM, Platt J, Bermudes D, Pawelek J. Melanoma × macrophage hybrids with enhanced metastatic potential. Clin Exp Metastasis 1998, 16:299-312.
52. Vignery A. Macrophage fusion: are somatic and cancer cells possible partners?. Trends Cell Biol 2005, 15:188-193.
53. Goldenberg DM, Pavia RA, Tsao MC. In vivo hybridisation of human tumour and normal hamster cells. Nature 1974, 250:649-651.
54. Jami J, Grandchamp S. Karyological properties of human-mouse somatic hybrids. Proc Natl Acad Sci USA 1971, 68:3097-3101. 389598, 4332007.
55. De Baetselier P, Roos E, Brys L, Remels L, Feldman M. Generation of invasive and metastatic variants of a non-metastatic T-cell lymphoma by in vivo fusion with normal host cells. Int JCancer 1984, 34:731-738.
56. Kerbel RS, Lagarde AE, Dennis JW, Donaghue TP. Spontaneous fusion in vivo between normal host and tumor cells: possible contribution to tumor progression and metastasis studied with a lectin-resistant mutant tumor. Mol Cell Biol 1983, 3:523-538. 368568, 6687920.
57. Pratt NR, Rees RC, Potter CW. In vivo tumour × host cell fusion in spontaneous Syrian hamster metastasis. Eur J Cancer Clin Oncol 1989, 25:1809-1816.
58. Busund LT, Killie MK, Bartnes K, Seljelid R. Spontaneously formed tumorigenic hybrids of Meth A sarcoma cells and macrophages in vivo. Int J Cancer 2003, 106:153-159.
59. Lagarde AE, Kerbel RS. Somatic cell hybridization in vivo and in vitro in relation to the metastatic phenotype. Biochim Biophys Acta 1985, 823:81-110.
60. Chakraborty A, Lazova R, Davies S, Backvall H, Ponten F, Brash D, Pawelek J. Donor DNA in a renal cell carcinoma metastasis from a bone marrow transplant recipient. Bone Marrow Transplant 2004, 34:183-186.
61. Yilmaz Y, Lazova R, Qumsiyeh M, Cooper D, Pawelek J. Donor Y chromosome in renal carcinoma cells of a female BMT recipient: visualization of putative BMT-tumor hybrids by FISH. Bone Marrow Transplant 2005, 35:1021-1024.
62. Andersen TL, Boissy P, Sondergaard TE, Kupisiewicz K, Plesner T, Rasmussen T, Haaber J, Kolvraa S, Delaisse JM. Osteoclast nuclei of myeloma patients show chromosome translocations specific for the myeloma cell clone: a new type of cancer-host partnership?. J Pathol 2007, 211:10-17.
63. Miller FR, Mohamed AN, McEachern D. Production of a more aggressive tumor cell variant by spontaneous fusion of two mouse tumor subpopulations. Cancer Res 1989, 49:4316-4321.
64. Hill RP, Chambers AF, Ling V, Harris JF. Dynamic heterogeneity: rapid generation of metastatic variants in mouse B16 melanoma cells. Science 1984, 224:998-1001.
65. Loustalot P, Algire GH, Legallais FY, Anderson BF. Growth and histopathology of melanotic and amelanotic derivatives of the Cloudman melanoma S91. J Natl Cancer Inst 1952, 12:1079-1117.
66. Tarin D. Tumor metastasis. Oxford Textbook of Pathology 1992, 607-633. Oxford, UK: Oxford University Press, O'D MJ, Isaacson P, Wright N.
67. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889, 1:571-579.
68. Bendich A, Wilczok T, Borenfreund E. Circulating DNA as a possible factor in oncogenesis. Science 1965, 148:374-376.
69. Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 1977, 37:646-650.
70. Bergsmedh A, Szeles A, Henriksson M, Bratt A, Folkman MJ, Spetz AL, Holmgren L. Horizontal transfer of oncogenes by uptake of apoptotic bodies. Proc Natl Acad Sci USA 2001, 98:6407-6411. 33481, 11353826.
71. Garcia-Olmo DC, Ruiz-Piqueras R, Garcia-Olmo D. Circulating nucleic acids in plasma and serum (CNAPS) and its relation to stem cells and cancer metastasis: state of the issue. Histol Histopathol 2004, 19:575-583.
72. Kramer SA, Farnham R, Glenn JF, Paulson DF. Comparative morphology of primary and secondary deposits of prostatic adenocarcinoma. Cancer 1981, 48:271-273.
73. Johnson DE, Appelt G, Samuels ML, Luna M. Metastases from testicular carcinoma. Study of 78 autopsied cases. Urology 1976, 8:234-239.
74. Guy CT, Cardiff RD, Muller WJ. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. MCB 1992, 12:954-961. 369527, 1312220.
75. van't Veer LJ, Dai H, Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536.
76. Ramaswamy S, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in primary solid tumors. Nat Genet 2003, 33:49-54.
77. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T, Berns EM, Atkins D, Foekens JA. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005, 365:671-679.
78. Chang HY, Sneddon JB, Alizadeh AA, Sood R, West RB, Montgomery K, Chi JT, Rijn M, Botstein D, Brown PO. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol 2004, 2:E7. 314300, 14737219.
79. Nuyten DS, Kreike B, Hart AA, Chi JT, Sneddon JB, Wessels LF, Peterse HJ, Bartelink H, Brown PO, Chang HY, Vijver MJ. Predicting a local recurrence after breast-conserving therapy by gene expression profiling. Breast Cancer Res 2006, 8:R62. 1779489, 17069664.
80. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004, 351:2817-2826.
81. Bernards R, Weinberg RA. A progression puzzle. Nature 2002, 418:823.
82. Lifsted T, Le Voyer T, Williams M, Muller W, Klein-Szanto A, Buetow KH, Hunter KW. Identification of inbred mouse strains harboring genetic modifiers of mammary tumor age of onset and metastatic progression. Int J Cancer 1998, 77:640-644.
83. Park YG, Zhao X, Lesueur F, Lowy DR, Lancaster M, Pharoah P, Qian X, Hunter KW. Sipa1 is a candidate for underlying the metastasis efficiency modifier locus Mtes1. Nat Genet 2005, 37:1055-1062. 2140048, 16142231.
84. Crawford NP, Ziogas A, Peel DJ, Hess J, Anton-Culver H, Hunter KW. Germline polymorphisms in SIPA1 are associated with metastasis and other indicators of poor prognosis in breast cancer. Breast Cancer Res 2006, 8:R16. 1483843, 16563182.
85. Schadt EE, Monks SA, Drake TA, Lusis AJ, Che N, Colinayo V, Ruff TG, Milligan SB, Lamb JR, Cavet G, Linsley PS, Mao M, Stoughton RB, Friend SH. Genetics of gene expression surveyed in maize, mouse and man. Nature 2003, 422:297-302.
86. Bystrykh L, Weersing E, Dontje B, Sutton S, Pletcher MT, Wiltshire T, Su AI, Vellenga E, Wang J, Manly KF, Lu L, Chesler EJ, Alberts R, Jansen RC, Williams RW, Cooke MP, de Haan G. Uncovering regulatory pathways that affect hematopoietic stem cell function using 'genetical genomics'. Nat Genet 2005, 37:225-232.
87. Chesler EJ, Lu L, Shou S, Qu Y, Gu J, Wang J, Hsu HC, Mountz JD, Baldwin NE, Langston MA, Threadgill DW, Manly KF, Williams RW. Complex trait analysis of gene expression uncovers polygenic and pleiotropic networks that modulate nervous system function. Nat Genet 2005, 37:233-242.
88. Yang H, Crawford N, Lukes L, Finney R, Lancaster M, Hunter KW. Metastasis predictive signature profiles pre-exist in normal tissues. Clin Exp Metastasis 2005, 22:593-603. 2048974, 16475030.
89. Lin EY, Nguyen AV, Russell RG, Pollard JW. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 2001, 193:727-740. 2193412, 11257139.
90. Wyckoff JB, Wang Y, Lin EY, Li JF, Goswami S, Stanley ER, Segall JE, Pollard JW, Condeelis J. Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res 2007, 67:2649-2656.
91. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, MacDonald DD, Jin DK, Shido K, Kerns SA, Zhu Z, Hicklin D, Wu Y, Port JL, Altorki N, Port ER, Ruggero D, Shmelkov SV, Jensen KK, Rafii S, Lyden D. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005, 438:820-827.